Ybiologics
Ybiologics is a biotech company. It has raised $25.3M across 1 round, most recently a $25.3M Convertible Note in August 2025.
Korea’s Leading Antibody Therapeutics Development Company
- Business Model
- B2B
- Website
- ybiologics.com
- Total Funding
- $25.3M
- Last Round
- $25.3M Convertible NoteAug 2025
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.
About
Y-Biologics develops novel antibody-based therapeutics through its proprietary pipeline and strategic partnerships, using antibody-discovery and engineering technologies. Its Multi-AbKine platform combines bispecific antibodies with cytokines to pursue cancers that are unresponsive or resistant to existing immunotherapies. The company also develops modalities including antibody humanization, pH-dependent antibodies, and antibody-drug conjugates for varied applications.
Summary
It has raised $25.3M in total across 1 round, most recently a $25.3M Convertible Note round in Aug 2025. Investors include AJU IB Investment, DSC Investment and Partners Investment.
Funding History
Aug 2025
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/ybiologics"><img src="https://indexed.vc/api/badge/company/ybiologics" alt="Ybiologics on Indexed.vc" width="260" height="76" /></a>